Roland L Dunbrack
Overview
Explore the profile of Roland L Dunbrack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Parker M, Meyer J, Golemis E, Dunbrack R
Cancer Res
. 2022 May;
82(13):2485-2498.
PMID: 35536216
Significance: Analysis of >700 RAS structures helps define an expanded landscape of active, inactive, and druggable RAS conformations, the structural impact of common RAS mutations, and previously uncharacterized RAS inhibitor-binding...
12.
Fowle H, Zhao Z, Xu Q, Wasserman J, Wang X, Adeyemi M, et al.
Elife
. 2021 Oct;
10.
PMID: 34661528
Protein phosphorylation is a reversible post-translation modification essential in cell signaling. This study addresses a long-standing question as to how the most abundant serine/threonine protein phosphatase 2 (PP2A) holoenzyme, PP2A/B55α,...
13.
Modi V, Dunbrack R
Nucleic Acids Res
. 2021 Oct;
50(D1):D654-D664.
PMID: 34643709
The active form of kinases is shared across different family members, as are several commonly observed inactive forms. We previously performed a clustering of the conformation of the activation loop...
14.
van Eeuwen T, Li T, Kim H, Gorbea Colon J, Parker M, Dunbrack R, et al.
Sci Adv
. 2021 Apr;
7(15).
PMID: 33827808
During transcription initiation, the general transcription factor TFIIH marks RNA polymerase II by phosphorylating Ser5 of the carboxyl-terminal domain (CTD) of Rpb1, which is followed by extensive modifications coupled to...
15.
Kelow S, Adolf-Bryfogle J, Dunbrack R
MAbs
. 2020 Nov;
12(1):1840005.
PMID: 33180672
Antibody variable domains contain "complementarity-determining regions" (CDRs), the loops that form the antigen binding site. CDRs1-3 are recognized as the canonical CDRs. However, a fourth loop sits adjacent to CDR1...
16.
Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, et al.
Oncotarget
. 2017 Jun;
8(25):39945-39962.
PMID: 28591715
Deficient mismatch repair (MMR) and microsatellite instability (MSI) contribute to ~15% of colorectal cancer (CRCs). We hypothesized MSI leads to mutations in DNA repair proteins including BRCA2 and cancer drivers...
17.
Kinch L, Li W, Schaeffer R, Dunbrack R, Monastyrskyy B, Kryshtafovych A, et al.
Proteins
. 2016 Jan;
84 Suppl 1:20-33.
PMID: 26756794
Protein target structures for the Critical Assessment of Structure Prediction round 11 (CASP11) and CASP ROLL were split into domains and classified into categories suitable for assessment of template-based modeling...
18.
Nicolas E, Arora S, Zhou Y, Serebriiskii I, Andrake M, Handorf E, et al.
Oncotarget
. 2015 Oct;
6(37):39614-33.
PMID: 26485759
Risk assessment for prostate cancer is challenging due to its genetic heterogeneity. In this study, our goal was to develop an operational framework to select and evaluate gene variants that...
19.
Shih J, Bashir B, Gustafson K, Andrake M, Dunbrack R, Goldstein L, et al.
J Natl Compr Canc Netw
. 2015 Aug;
13(8):947-52.
PMID: 26285240
Next-generation sequencing of primary and metachronous metastatic cancer lesions may impact patient care. We present a case of relapsed metastatic breast cancer with a dominant pulmonary lesion originally identified as...
20.
Plimack E, Dunbrack R, Brennan T, Andrake M, Zhou Y, Serebriiskii I, et al.
Eur Urol
. 2015 Aug;
68(6):959-67.
PMID: 26238431
Background: Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy is the standard of care for muscle-invasive bladder cancer (MIBC), with 25-50% of patients expected to achieve a pathologic response. Validated biomarkers predictive...